NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES

Informations projet

NeoVasculoStop

N° de convention de subvention: 101047120

DOI

10.3030/101047120

Date de signature de la CE 28 Mars 2022

Date de début 1 Mars 2022

Date de fin 30 Septembre 2026

Financé au titre de

• The European Innovation Council (EIC)

Coût total

€ 2 988 434,75

Contribution de l’UE

€ 2 988 434,75

Coordonné par

EXPERIMENTICA OY
Finland

Periodic Reporting for period 2 - NeoVasculoStop (NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RETINOPATHIES)

Période du rapport: 2023-03-01 au 2024-08-31

Résumé du contexte et des objectifs généraux du projet

The specific objectives of the project are laid down in a way that, at the project closure, one lead molecule (a modified inhibitor), one follow-up molecule, furthermore all the results and the documentation be available and collected for a human phase I clinical trial. The steps leading to these objectives can be summarized as follows:
We will synthetize modified VEGFR inhibitors based on in silico work.
We will test the best candidate molecules on cultured human retinal microvascular endothelial cells (HRMEC) to verify their potential to block neovascularization.
We will produce at least one further molecule derived from a different VEGFR inhibitor via a specific chemical modification.
We will test the enrichment of the compounds in the retina by exposure to natural light and upon artificial irradiation.
We will test the efficiency of the compounds.
We will prove the absence of toxicity and verify the tolerability of the modified compounds.
We will produce all the documents required for the human phase I clinical trial based on the experiments above.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Following deliverables were submitted during the reporting period (RP2):

D1.6 Midterm plan for the exploitation and dissemination of project results
D1.7 Data Management Plan RP2 (DMP)
D2.3 Interim report on biological testing of modified analogues in an in vitro biochemical VEGFR assay system
D2.4 Interim report on biological testing of modified analogues in a cellular in vitro biological system
D2.5 Interim report on activation of modified analogues
D3.1 The effect of compounds on HRMEC migration measured as a fluorescence signal
D3.2 The amount of retinal tissue and blood samples transferred to the SE
D3.4 The two best modified inhibitors selected

Following milestones were achieved during the RP2:
M4 Identification of the two best modified inhibitors

During RP2, there have not been any changes in the consortium. Consortium has achieved good research progress and implementation levels.
The detailed information on the achievements described above and progress towards future objectives will be presented in the Part B of this report.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Project meeting was held on May 4, 2023 in Prague, Czechia.
Review meeting for RP1 was held (online) on May 5, 2023, consortium in Prague, Czechia.
Project meetings were held on November 15-16, 2023 in Budapest, Hungary and on May 22-23, 2024 in Kuopio, Finland.

PCT/HU2023/050073, International publication number: WO 2024/095026 A1

In addition, technical meetings, executive board and general assembly meetings were held to monitor the progress of the project and discuss the scientific plans and results.

Logo